Mural Oncology plc
NASDAQ: MURA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Caroline J. Loew
- Employees
- 116
- Headquarters
- Dublin, Ireland
- IPO year
- 2023
- Market cap
- $35.4M
- Website
- https://www.muraloncology.com
Loading MURA…
Loading profile data…Frequently asked questions about MURA
What does Mural Oncology plc (MURA) do?
Mural Oncology Plc, a clinical-stage company, is dedicated to discovering and advancing immune-based therapies for individuals battling cancer. Its primary drug candidate, nemvaleukin alfa, is currently under investigation as a standalone agent for mucosal melanoma and in partnership with pembrolizumab for platinum-resistant ovarian cancer. Addi...
Where does MURA trade?
Mural Oncology plc (MURA) trades on the NASDAQ Global Market.
What sector is MURA in?
Mural Oncology plc (MURA) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Mural Oncology plc?
Caroline J. Loew is the chief executive officer of Mural Oncology plc (MURA).
Where is Mural Oncology plc headquartered?
Mural Oncology plc is headquartered in Ireland.
Does MURA pay a dividend?
Mural Oncology plc (MURA) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did MURA go public?
Mural Oncology plc (MURA) completed its initial public offering in 2023.